摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[5-(1-ethyl-piperidin-4-yloxy)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine | 1231930-05-4

中文名称
——
中文别名
——
英文名称
[5-(1-ethyl-piperidin-4-yloxy)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine
英文别名
N-[5-(1-ethylpiperidin-4-yl)oxypyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
[5-(1-ethyl-piperidin-4-yloxy)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine化学式
CAS
1231930-05-4
化学式
C27H31F2N7O
mdl
——
分子量
507.586
InChiKey
PUMTVPQMFAWWBI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.8
  • 重原子数:
    37
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    81
  • 氢给体数:
    1
  • 氢受体数:
    9

文献信息

  • PROTEIN KINASE INHIBITORS
    申请人:COATES David A.
    公开号:US20100160340A1
    公开(公告)日:2010-06-24
    The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    本发明提供了化合物的结构式(I):或其药用可接受的盐,可用于治疗细胞增殖性疾病。
  • [EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASES
    申请人:LILLY CO ELI
    公开号:WO2010075074A1
    公开(公告)日:2010-07-01
    The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    本发明提供了式(I)的化合物或其药学上可接受的盐,其在治疗细胞增殖性疾病方面是有用的。
  • Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
    申请人:Acerta Pharma B.V.
    公开号:US20170224819A1
    公开(公告)日:2017-08-10
    Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ, a Janus kinase-2 (JAK-2) inhibitor, a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor, and/or a Bruton's tyrosine kinase (BTK) inhibitor are described. In certain embodiments, the invention includes therapeutic combinations of a cyclin-dependent kinase-4/6 (CDK4/6) inhibitor and a BTK inhibitor, a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a JAK-2, PI3K-δ, and BTK inhibitor.
  • US7855211B2
    申请人:——
    公开号:US7855211B2
    公开(公告)日:2010-12-21
查看更多